A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis

BACKGROUND: Treatment options to address the hyponatremia induced by the syndrome of inappropriate antidiuresis (SIAD) are inadequate. The sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin promotes osmotic diuresis via urinary glucose excretion and therefore, might offer a novel treatme...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Am Soc Nephrol
Hlavní autoři: Refardt, Julie, Imber, Cornelia, Sailer, Clara O., Jeanloz, Nica, Potasso, Laura, Kutz, Alexander, Widmer, Andrea, Urwyler, Sandrine A., Ebrahimi, Fahim, Vogt, Deborah R., Winzeler, Bettina, Christ-Crain, Mirjam
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Nephrology 2020
Témata:
Clinical Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7062212/
https://ncbi.nlm.nih.gov/pubmed/32019783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2019090944
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky